• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

2024 Glaucoma 360 annual event: One-of-a-kind learning opportunity

News
Article

Sharing, learning, networking, collaborating

(image Credit: AdobeStock/bennymarty)

(image Credit: AdobeStock/bennymarty)

The Glaucoma Research Foundation is busy putting the finishing touches on the 2024 Glaucoma 360 annual meeting, covering all aspects of glaucoma diagnosis, treatment, technological updates, and treatments in the industry pipeline.

The venue for the 3-day event is the historic Westin St. Francis San Francisco on Union Square, 335 Powell Street, San Francisco.

The following are the important dates to bookmark:

Andrew Iwach, MD, a cofounder of Glaucoma 360, and Executive Director of the Glaucoma Center of San Francisco, commented, “Glaucoma 360 is truly a one-of-a-kind learning opportunity where attendees can be updated on the latest developments and treatment and management options in glaucoma. This is a dynamic field; for example, in the past few days, the FDA approved the Belkin laser and the Glaukos iDose Sustained Release device. Glaucoma 360 is the place to be with all the key leaders in the glaucoma space present, presenting, and available for interaction.”

Annual Gala

The Annual Gala, the biggest fundraising event for the Glaucoma Research Foundation, includes a benefit dinner that celebrates outstanding leadership in ophthalmology, the inspiring achievements of people living with glaucoma, and the transformative generosity of Foundation supporters, many of whom are patients and their loved ones, according to the Foundation’s website.

During the event, the Foundation takes the opportunity to recognize individuals who have contributed substantially during 2023 to the fight against glaucoma. This year’s recipients will receive the Catalyst Award, the Visionary Award, and the President’s Award.

The Annual Gala is an in-person-only event that will run from 6:00 to 9:00 pm Pacific Standard Time (PST). Registration for the event is required.

13th Annual New Horizons Forum

This 12-hour in-person-only event, which is considered the heart of the conference, will run from 7 am to 7 pm PST.

The goal of the Forum is to bring together key clinical, industry, financial, and FDA leaders in a setting that facilitates unique exchange on research innovation and advances in glaucoma treatment with the goal of speeding the translation of new ideas into clinical practice.

Morning and afternoon sessions of presentations are planned. The morning session runs from 8 am to 12:25 pm PST and covers the following topics: Opening Keynote Address—the Drs. Henry and Frederick Sutro Memorial Lecture; Morning Catalyst; Through the Eye of Marketscope; Transforming Glaucoma Care: Addressing Unmet Needs; Here's To The Doers! - Glaucoma Devices; and an Industry Panel Discussion.

The Keynote Speaker during the morning session is Sean Ianchulev, MD, MPH. He is Professor of Ophthalmology, Director of Innovation and Technology, New York Eye and Ear of Mount Sinai, Icahn School of Medicine, New York, and CEO of Eyenovia Inc. and Iantrek, Inc.

Ianchulev will deliver the 2024 Drs. Henry and Frederick Sutro Memorial Lecture titled "The Innovation Journey of an iDoctor."

The Forum’s afternoon session will go from 1:00 to 7 pm PST and cover these topics: Afternoon Catalyst; Navigating the Evolving Payer Landscape; Glaucoma Beyond the Office: Maintaining Care Outside the Clinic; Industry Panel Discussion: Pharmaceuticals; Medications in Motion: Innovations in Glaucoma Drugs and Drug Delivery; Investing in Sight: Glaucoma Venture Capital Insights; and Where Do We Go from Here? Keeping the Focus on Innovation. The evening wraps up with a reception following the presentations.

Registration for the event can be found online.

28th Annual Glaucoma Symposium CME

This segment of Glaucoma 360 is scheduled for 7:30 am to 1:00 pm PST.

This Symposium is intended for practicing ophthalmologists and will highlight the latest advances in glaucoma management, medications, and surgical techniques. Physicians can become acquainted with the latest updates on the most effective treatment options for patients and receive CME credits at the same time.

The Keynote Speaker during the Symposium is Ronald L. Fellman, MD, who will deliver the Shaffer-Hetherington-Hoskins Lecture. He is the founder and President of Glaucoma Associates of Texas, past President of the American Glaucoma Society, and recipient of the Glaucoma Research Foundation's Catalyst Award. He co-invented both 360-degree circumferential trabeculotomy ab externo in 1968, GATT in 2011, and first described the episcleral venous fluid wave.

Advance registration is required for the Symposium, which is an in-person-only event. Registration can be found online and no registration fee is required.

9th Annual Optometric Glaucoma Symposium

This 9th annual CME for licensed practicing optometrists, which will run from 1:30 to 5:30 pm PST, will highlight the latest advances in glaucoma. The Symposium is presented by the Glaucoma Research and Education Group in partnership with Glaucoma Research Foundation.

There is no registration fee for this in-person-only event. Advance registration is required.

Related Videos
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.